Figures & data
Figure 1 Schematic diagram of adverse drug events selection from Vigibase data used to filter the records.
![Figure 1 Schematic diagram of adverse drug events selection from Vigibase data used to filter the records.](/cms/asset/6b84bad3-88cf-4393-930e-dbd62c670e63/didr_a_287934_f0001_c.jpg)
Table 1 Characteristics of Adverse Drug Events (194 ADEs Reported from 93 Individuals) Reported for Favipiravir in WHO Database
Table 2 Adverse Drug Events Suspected to Be Caused by Favipiravir, as Reported in the WHO Database (N=93)
Figure 2 Distribution of Adverse Drug events reported with Favipiravir use in COVID-19 across continents in Vigibase.
![Figure 2 Distribution of Adverse Drug events reported with Favipiravir use in COVID-19 across continents in Vigibase.](/cms/asset/39affa7a-e309-47c4-8c4f-a515531558d6/didr_a_287934_f0002_c.jpg)
Table 3 Distribution of Characteristics of Different Adverse Drug Events Suspected to Be Caused by Favipiravir Between Age <64 and >64 Years
Table 4 Comparison of Serious and Non-Serious Adverse Drug Events Suspected to Be Caused by Favipiravir Among Various Study Characteristics (N = 194)